Advanced Recurrent Ovarian Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

elveInsight's, "Advanced Recurrent Ovarian Cancer Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the Advanced Recurrent Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Recurrent Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Recurrent Ovarian Cancer Research. Learn more about our innovative pipeline today! @ Advanced Recurrent Ovarian Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

* June 2024:- Valerio Therapeutics - This is a phase 1/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and PK/PD of VIO-01 alone or in combination with other anti-cancer therapies in select participants with advanced HRRm or HRD+ solid tumors (i.e. BRCA1/2 mutated breast cancer, HRR mutated prostate cancer) or HRRm/HRD+/HRP (phase 1 only) recurrent ovarian cancer.
* June 2024:- A2 Biotherapeutics Inc .- A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod Trademark CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
* DelveInsight's Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
* The leading Advanced Recurrent Ovarian Cancer Companies such as IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen Inc., Glycotope GmbH, and others.
* Promising Advanced Recurrent Ovarian Cancer Therapies such as VIO-01, ELU001, MK-3475 (pembrolizumab), Cyclophosphamide, Pembrolizumab, Ipilimumab, A2B694, JPI-547, Fludarabine , and others.

Stay informed about the cutting-edge advancements in Advanced Recurrent Ovarian Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Recurrent Ovarian Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Recurrent Ovarian Cancer Emerging Drugs Profile

* Maveropepimut S: IMV

Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV's new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S' ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients' quality of life.

* ELU 001: Elucida Oncology

ELU001 is a novel, first-in-class, new molecular entity described as a C'Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C'Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001's high avidity is believed to promote internalization into FR overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

* A166: Klus Pharma

A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

Learn more about Advanced Recurrent Ovarian Cancer Drugs opportunities in our groundbreaking Advanced Recurrent Ovarian Cancer Research and development projects @ Advanced Recurrent Ovarian Cancer Unmet Needs [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Discover the latest advancements in Advanced Recurrent Ovarian Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Recurrent Ovarian Cancer Companies and Drugs

* TCR2 Therapeutics: Fludarabine
* Onconic Therapeutics Inc.: JPI-547
* A2 Biotherapeutics Inc.: A2B694
* ImmunoVaccine Technologies, Inc. (IMV Inc.): Cyclophosphamide/Pembrolizumab
* Valerio Therapeutics: VIO-01

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

* Coverage- Global
* Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen Inc., Glycotope GmbH, and others.
* Advanced Recurrent Ovarian Cancer Therapies- VIO-01, ELU001, MK-3475 (pembrolizumab), Cyclophosphamide, Pembrolizumab, Ipilimumab, A2B694, JPI-547, Fludarabine, and others.
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Recurrent Ovarian Cancer Pipeline on our website @ Advanced Recurrent Ovarian Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Advanced Recurrent Ovarian Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Recurrent Ovarian Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Maveropepimut S: IMV
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Recurrent Ovarian Cancer Key Companies
* Advanced Recurrent Ovarian Cancer Key Products
* Advanced Recurrent Ovarian Cancer- Unmet Needs
* Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
* Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
* Advanced Recurrent Ovarian Cancer Analyst Views
* Advanced Recurrent Ovarian Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-recurrent-ovarian-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services



This release was published on openPR.